10月5日，查尔斯河盘中上涨5.34%，报305.68美元。消息面上，瑞银9月30日将其评级从中性上调至买入并将目标价从175美元大幅提升至357美元，大幅超越市场平均423.54美元的目标预期。同时医疗健康领域新合作加速推进，公司于9月29日与PMGC子公司签署协议，为两款GLP-1减肥疗法配套益生菌产品提供质粒拷贝数检测服务。
双利好驱动下公司股价突破关键阻力位，结合近期强劲的财报表现（Q2营收10.04亿美元超预期9.8%）以及2030年年化5%-7%营收增长的长期指引，市场对公司在NAM方法学整合与生物制药服务领域的领先地位持续看好。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.